Patent · US Active

LILRB4-binding antibody and methods of use thereof

US12180277B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Naveen Sharma · Houston, US
James Allison · New York, US

Key dates

Filing date	Mar 2, 2020
Grant date	Dec 31, 2024
Priority date	—
Expiry date	Apr 28, 2042

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70503
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are LILRB4-binding antibodies and methods of treating cancer by administering the LILRB4-binding antibodies alone or in combination with other therapies. Recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.